Gerald stated on the conference call that mainstream media outlets aren't really interested in us until we have data to report. I would expect at that time the tweets will decline as he'll be spending more time doing interviews with major league media outlets, not the minor leagues we've been doing.
Not discounting the coverage they provide, but the Fox News story was the only one I saw that provided a substantial impact on demand and moved the share price significantly higher. Data and major media coverage could provide that with sustainability and not the subsequent sell-offs... especially after the partner or buyout offers start coming in. :-)
Have to agree with you on that aspect. Way to much time on twitter. Repeating the same thing over and over again. Testing, testing! Think time could be better spent looking for new clients for provista, etc. Talk is cheap with regards to the CC. Same as what was done with AMBS. Hope the outcome is better with TODOS.
Todos has a nutritional supplement on the market and I would like GC to provide a chart on what that revenue stream has been over Q3 & Q4 of 2021. My first Tollovid (Amazon) order was $400, 2x $100 and 1x $200. I plan on repeating that quarterly. A Tollovid revenue projection for 2022 please. What does expansion into India and Asia look like for Tollovid?
I like to see multiple potential revenue streams with testing, therapeutics and supplements. Testing and therapeutics are capital intensive. They take time and a large corporate structure. They are both Highly Regulated Industries. Can Todos compete or partner with others that are willing to challenge more established organizations? I'm skeptical. That leaves the supplement business and it looks like that has huge potential. I hope there is a focus on that and the promotion of Tollovid is not limited to Twitter. Maybe Greece will get the ball rolling in Europe and serve as a model.
Market Data 
Markets 
AI
